Modus Therapeutics will present new research on sevuparin for chronic kidney disease (CKD) with anemia at the 32nd Symposium ...

The European Commission has approved ROMVIMZA (vimseltinib) for adult patients with symptomatic tenosynovial giant cell ...

Nxera Pharma and Cancer Research UK have announced the first patient has been dosed in a phase 2a trial of HTL0039732, an ...

Among patients with HS, HiSCR75, HiSCR90 and HiSCR100 responses seen at one year were sustained and improved to three years ...

The MHRA has approved vorasidenib (Voranigo) for patients aged 12 and above with grade 2 astrocytoma or oligodendroglioma ...

AstraZeneca’s Imfinzi (durvalumab) has been approved for NHS use in England and Wales for adults with limited-stage small ...

Thierry Van Nieuwenhove, CEO at Quotient Sciences, said: “This is a pivotal moment for RNA drug development. The combined ...

Eisai has presented new clinical data for its investigational orexin 2 receptor agonist E2086 at the World Sleep 2025 ...

Dr Deepika Jalota, Chief Development Officer, said: “These phase 2 PYNNACLE interim trial data illustrate that rezatapopt, a ...

Bluejay Therapeutics has enrolled the first patient in AZURE-2, a global phase 3 clinical trial evaluating brelovitug ...

Lundbeck has presented new clinical data on eptinezumab at the 2025 International Headache Congress in São Paulo, ...

Merck has announced positive phase 3 results for Capvaxive, its 21-valent pneumococcal conjugate vaccine, in children and ...